Loading...
•
Mar 31, 2022
Guardant Health Q1 2022 Earnings Report
Reported a revenue increase of 22% year over year, driven by strong growth in clinical and biopharma testing volumes.
Key Takeaways
Guardant Health reported a 22% increase in revenue for the first quarter of 2022, driven by significant growth in clinical and biopharma testing volumes. The company launched its Shield LDT screening test and expanded partnerships, while also receiving regulatory approvals and Medicare coverage for key tests.
Revenue reached $96.1 million, a 22% increase compared to the first quarter of 2021.
Clinical tests grew by 47% and biopharmaceutical tests grew by 45% year-over-year, with 27,100 and 5,100 tests reported, respectively.
Shield LDT, a blood-based test for early-stage colorectal cancer detection, was launched.
Partnership with Epic was announced, expanding access to Guardant Health's tests to over 250 million patients.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health continues to expect full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.